Clinical Trial Update: Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 safety study evaluating intravenously administered recombinant vaccinia virus in patients with metastatic, refractory colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Recombinant Vaccinia Virus

Snippet

Sponsor: Jennerex Biotherapeutics | Conditions: Carcinoma, Colorectal | Phase 1 | Status: COMPLETED